Peptides for focus and dopamine: what TikTok gets wrong

What did @alexfraysse_coaching actually say?

The creator claims that retatrutide, taken at a low dose, produces "superhuman" focus, kills cravings, and functions like taking ADHD medication, but without the medication. They report nine weeks of personal use and describe their motivation and productivity as dramatically elevated. The framing is anecdotal but confident: "I just know what to do and I just do it."

To be clear about what is being asserted here: this is a coaching account on TikTok recommending an investigational peptide as a cognitive and behavioral intervention for people with ADHD. That is a medical claim about an unapproved compound, dressed up as a personal story. The disclaimer-free delivery is worth noting before we get into the science.

Does the science back this up?

Not in any direct way. There is no published clinical trial examining retatrutide's effects on ADHD symptoms, executive function, or dopamine-related focus. The compound is still in Phase 2 trials for obesity and metabolic disease, and cognitive outcomes are not a primary or secondary endpoint in any registered study as of 2024.

What we do know comes from the GLP-1 receptor agonist class more broadly. Retatrutide is a triple agonist, hitting GLP-1, GIP, and glucagon receptors simultaneously. Blanco-Gandia et al. (2023, Frontiers in Pharmacology) reviewed GLP-1 receptor signaling in the brain and found evidence for dopaminergic modulation in reward circuits, particularly the nucleus accumbens. Separate work by Holt et al. (2022, Diabetes, Obesity and Metabolism) documented reduced impulsivity and cravings in patients on semaglutide. These findings are real, but extrapolating them to retatrutide as an ADHD treatment is a long, unsupported leap.

What did they get wrong (or right)?

Let's start with what has some basis. The idea that GLP-1 class drugs affect motivation and craving is not invented. The "cravings are completely flat" observation is consistent with what researchers and clinicians have documented in GLP-1 users. That part is plausible and matches the mechanistic literature on reward suppression.

Where the video goes wrong is describing this as "like taking ADHD medication without having to take ADHD medication." ADHD medications, specifically stimulant-class drugs, work through well-characterized norepinephrine and dopamine reuptake inhibition. Retatrutide does not work through those pathways. The subjective feeling of improved focus and motivation does not make two compounds mechanistically equivalent or therapeutically interchangeable. Saying so to an audience that includes people managing an actual neurodevelopmental condition is irresponsible. Nobody should stop, start, or adjust ADHD treatment based on this video.

The "no one's talking about the side effect" framing also misrepresents what side effects are. What the creator describes, increased focus and motivation, would be a reported effect, not a side effect. And retatrutide does have documented side effects from trial data: nausea, vomiting, gastrointestinal distress, and questions around lean mass loss.

What should you actually know?

Retatrutide is an investigational compound. It is not FDA-approved for any indication. It is not approved for ADHD, focus enhancement, or cognitive optimization. Any retatrutide available outside of a registered clinical trial is compounded, and compounded versions have not been evaluated for purity, potency, or safety in the same way trial-grade material has been.

The GLP-1 class does appear to influence brain reward circuitry in ways that affect motivation and craving, and this is a legitimate area of active research. But there is a significant difference between "interesting mechanistic signal" and "miracle for focus and productivity." The latter is marketing language, not clinical language. If you are considering any peptide therapy, that conversation starts with a licensed provider who can evaluate your full health picture, not a coaching account on TikTok.